Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs. The company also provides Derwent products, which include Derwent Innovation, Techstreet, and IP Professional Services that enables its customers to evaluate the novelty of potential new products, confirm freedom to operate with respect to their product design, help them secure patent protection, assess the competitive technology landscape, and ensure that their products comply with required industry standards; CompuMark products, such as trademark screening, searching, and watching products and services for businesses and law firms; and MarkMonitor products, which helps enterprises to establish, manage, optimize, and protect their online presence. It serves government and academic institutions, life science companies, and research and development corporations in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc is headquartered in London, the United Kingdom.
IPO Year: 2019
Exchange: NYSE
Website: clarivate.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2024 | Outperform → Mkt Perform | William Blair | |
| 12/15/2023 | $8.00 | Equal Weight → Underweight | Wells Fargo |
| 10/16/2023 | $10.00 → $8.50 | Hold → Buy | Jefferies |
| 9/8/2023 | $8.00 → $7.00 | Equal Weight → Underweight | Barclays |
| 8/25/2023 | $9.00 → $8.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 8/7/2023 | $10.00 → $6.00 | Neutral → Underperform | BofA Securities |
| 8/4/2023 | $15.00 → $8.00 | Overweight → Equal Weight | Wells Fargo |
| 6/13/2023 | $11.00 | Outperform | Oppenheimer |
| 3/15/2023 | Neutral | BofA Securities | |
| 2/6/2023 | $11.00 → $12.00 | Overweight → Equal-Weight | Morgan Stanley |
8-K - CLARIVATE PLC (0001764046) (Filer)
8-K/A - CLARIVATE PLC (0001764046) (Filer)
10-Q - CLARIVATE PLC (0001764046) (Filer)
8-K - CLARIVATE PLC (0001764046) (Filer)
8-K - CLARIVATE PLC (0001764046) (Filer)
10-Q - CLARIVATE PLC (0001764046) (Filer)
8-K - CLARIVATE PLC (0001764046) (Filer)
8-K - CLARIVATE PLC (0001764046) (Filer)
25-NSE - CLARIVATE PLC (0001764046) (Subject)
8-K - CLARIVATE PLC (0001764046) (Filer)
4 - CLARIVATE PLC (0001764046) (Issuer)
4 - CLARIVATE PLC (0001764046) (Issuer)
4 - CLARIVATE PLC (0001764046) (Issuer)
4 - CLARIVATE PLC (0001764046) (Issuer)
4 - CLARIVATE PLC (0001764046) (Issuer)
4 - CLARIVATE PLC (0001764046) (Issuer)
4 - CLARIVATE PLC (0001764046) (Issuer)
4 - CLARIVATE PLC (0001764046) (Issuer)
4 - CLARIVATE PLC (0001764046) (Issuer)
4 - CLARIVATE PLC (0001764046) (Issuer)
4 - CLARIVATE PLC (0001764046) (Issuer)
4 - CLARIVATE PLC (0001764046) (Issuer)
SC 13G/A - CLARIVATE PLC (0001764046) (Subject)
SC 13G - CLARIVATE PLC (0001764046) (Subject)
SC 13D/A - CLARIVATE PLC (0001764046) (Subject)
SC 13G/A - CLARIVATE PLC (0001764046) (Subject)
SC 13G/A - CLARIVATE PLC (0001764046) (Subject)
SC 13D/A - CLARIVATE PLC (0001764046) (Subject)
SC 13D/A - CLARIVATE Plc (0001764046) (Subject)
SC 13D/A - CLARIVATE Plc (0001764046) (Subject)
SC 13D - CLARIVATE Plc (0001764046) (Subject)
SC 13D - CLARIVATE Plc (0001764046) (Subject)
William Blair downgraded Clarivate from Outperform to Mkt Perform
Wells Fargo downgraded Clarivate from Equal Weight to Underweight and set a new price target of $8.00
Jefferies upgraded Clarivate from Hold to Buy and set a new price target of $8.50 from $10.00 previously
Barclays downgraded Clarivate from Equal Weight to Underweight and set a new price target of $7.00 from $8.00 previously
RBC Capital Mkts downgraded Clarivate from Outperform to Sector Perform and set a new price target of $8.00 from $9.00 previously
BofA Securities downgraded Clarivate from Neutral to Underperform and set a new price target of $6.00 from $10.00 previously
Wells Fargo downgraded Clarivate from Overweight to Equal Weight and set a new price target of $8.00 from $15.00 previously
Oppenheimer initiated coverage of Clarivate with a rating of Outperform and set a new price target of $11.00
BofA Securities resumed coverage of Clarivate with a rating of Neutral
Morgan Stanley downgraded Clarivate from Overweight to Equal-Weight and set a new price target of $12.00 from $11.00 previously
Concludes the appointments for business leaders of its three market segments LONDON, April 26, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, announced today that it has appointed Henry Levy as President, Life Sciences & Healthcare, effective May 1, 2023. Henry joins from Veeva Systems, a global leader in cloud software for the life sciences industry, where he most recently served as President, Global R&D and Quality, with responsibility for driving sales across the segment. Jonathan Gear,
Appointing the second of three business leaders for its newly created market segments LONDON, April 19, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Bar Veinstein will join the company as President, Academia & Government, effective April 24, 2023. Bar joins from Taranis, an AI-powered crop intelligence provider, where he was Chief Executive Officer focusing on driving business growth, improving customer satisfaction and accelerating the company's artificial intelligence (AI) strategy. He previously spent 11 years with the Ex Libris Group, now part of Clarivate, and under his leader
Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Board LONDON, March 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.
Andy Snyder to Become Chair of the Board in October Board appoints Jerre Stead to the role of Chairman Emeritus LONDON, Sept. 1, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today that Jonathan Gear has assumed the role of Chief Executive Officer with the retirement of Jerre Stead from that role. As previously announced in July, Mr. Stead has transitioned to non-executive chair of the board of directors. Following the October board meeting, he will retire from the
LONDON, July 11, 2022 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that Jerre Stead, Executive Chair and Chief Executive Officer, is retiring from his CEO role effective September 1, 2022, but will continue as Non-Executive Chair of the Board of Directors. During Mr. Stead's tenure as Clarivate CEO, the company has nearly tripled in size both in revenue and colleague population, delivered strong cash flow, completed multiple strategic acquisitions, and aligned into a customer- and colleague-centric enterprise.
MAUMEE, Ohio, Dec. 1, 2021 /PRNewswire/ -- Dana Incorporated (NYSE:DAN) today announced the appointment of Dana veteran Timothy R. Kraus as senior vice president and chief financial officer. Mr. Kraus succeeds Jonathan Collins, who will be leaving Dana to become CFO of Clarivate plc (NYSE:CLVT), a world-leading information and analytics provider. Mr. Collins will continue with Dana through Dec. 15 to assist with the transition. An officer of the company with more than a decade of experience at Dana, Mr. Kraus most recently served as senior vice president of finance and treas
LONDON, Oct. 18, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT, CLVT PRA))), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the appointment of Tiffani Shaw as Chief of Staff reporting to Jerre Stead, Executive Chairman and Chief Executive Officer at Clarivate. In this newly created role, Shaw will plan and direct administrative activities for the office of the CEO and be a member of the Executive Leadership Team. She will join Clarivate on November 1. Shaw joins Clarivate from The University of Iowa Center fo
LONDON, April 12, 2021 /CNW/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the appointment of Julie Wilson as Chief People Officer (CPO). She replaces Andrea Degutis who retires after four years at the helm of Clarivate Human Resources. "Andrea has been an invaluable partner to me and the executive team during a period of high growth and unprecedented circumstances, including the difficult challenge of leading us through the pandemic and initiating a major workplace transformat
LONDON, April 12, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the appointment of Julie Wilson as Chief People Officer (CPO). She replaces Andrea Degutis who retires after four years at the helm of Clarivate Human Resources. "Andrea has been an invaluable partner to me and the executive team during a period of high growth and unprecedented circumstances, including the difficult challenge of leading us through the pandemic and initiating a major workplace tran
Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON, Jan. 16, 2025 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated 2024 Year in Review series. This multipart special report offers an in-depth analysis of the therapeutic trends, regulatory actions and economic shifts that defined biopharma, med tech and scientific innovation over the past year while forecasting key developments for 2025. As the biopharma and med-tech indu
New modular analytics solution empowers commercial teams to optimize strategies and improve patient outcomes LONDON, Jan. 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of DRG Fusion, an innovative platform to support commercial analytics in life sciences. Powered by integrated real-world data and built by clinical and data science experts, Fusion provides biopharma and medtech organizations with the tools to understand and act in varied disease and competitive landscapes — eliminating the complexities of raw data management.
LONDON, Dec. 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today announced that its Board of Directors (the "Board") authorized a new share repurchase program of up to $500 million of the Company's outstanding ordinary shares through open-market purchases for a period of two years, from January 1, 2025 through December 31, 2026. The new share repurchase program replaces the current share repurchase program which terminates December 31, 2024, under which the Company repurchased $300 m
Faster and more relevant results to empower critical IP decision-making LONDON, Dec. 12, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of AI Search in Derwent™. Combining artificial intelligence (AI) with the premier source of global patent data, Derwent World Patents Index (DWPI)™, this solution will enable intellectual property (IP) professionals to make reliable innovation decisions by finding more relevant patents in less time. The new AI Search available today in Derwent Innovation use
Revealing highly active specialties in sciences and social sciences LONDON, Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, and the Chinese Academy of Sciences (CAS) today released 2024 Research Fronts™, identifying the most dynamic and rapidly growing specialties in sciences and social sciences. This marks the eleventh annual collaboration between the two organizations, with the report launched at a ceremony held in Beijing today. The report identifies 125 Research Fronts, comprising 110 'hot' Fronts and 15 'e
Enhancing operational efficiency for leading air conditioner manufacturer LONDON, Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, announced today that Daikin Industries, Ltd. (Daikin) has selected IPfolio™ from Clarivate. The leading air conditioner manufacturer will utilize this solution to optimize its intellectual property (IP) assets, enabling more confident strategic decision-making and sustainable growth. IPfolio will support Daikin's IP teams in maximizing operational efficiency, keeping pace with increa
New seven-part series explores disparities in care, funding and innovation impacting half the world's population LONDON, Nov. 21, 2024 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has launched its new special series, 'Healing the Health Divide.' This seven-part series sheds light on the persistent disparities in women's health research, funding, and treatment. Women make up half of the global population, yet their health remains consistently underserved. Research and treatments have traditionally fo
Prioritizing research integrity with enhanced filters to address publication and citation manipulation LONDON, Nov. 19, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today revealed its 2024 list of Highly Cited Researchers™ – influential researchers at universities, research institutes and commercial organizations around the world who have demonstrated significant and broad influence in their field(s) of research. Analysts at the Institute for Scientific Information (ISI)™ have recognized 6,636 Highly Cited Researche
New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON, Nov. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership with Healthcare Executive, published by the China Pharmaceutical Enterprises Association, today announced the release of a new report, A Decade of Innovation, A Decade to Come. Over the past decade, Mainland China's biopharmaceutical sector has rapidly advanced to become a global leader in innovation, rankin
Recognizing Roper St. Francis Healthcare, Bon Secours Mercy Health, and Bronson Methodist Hospital for excellence in Physician and Hospital Groups LONDON, Nov. 13, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, announced the 2023 winners of the Clarivate Healthcare Business Insights™ annual Revenue Cycle Awards. Now in its 12th year, the Revenue Cycle Awards recognize U.S.-based healthcare organizations for exceptional performance on revenue cycle KPIs, based on data from their most recent and preceding full fiscal years. The 2023 recipients include Roper St. Francis Healthcare (Physician Group) – SC; Bon Secours Mercy Health (Physici
LONDON, Nov. 6, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Revenues of $622.2 million decreased 3.9%Organic revenues decreased 2.6%, as an increase in subscription revenues of 0.6% was offset by a decrease in re-occurring revenues of 1.1% and transactional and other revenues of 13.6%Net loss of $65.6 million; Net loss per diluted share of $0.09Adjusted net income(1) of $134.1
LONDON, Oct. 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the third quarter 2024 before the market opens on Wednesday, November 6, 2024. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com. The Company will host a conference call and webcast at 9:00 AM Eastern Time on Wednesday, November 6, 2024 to review the results. The webcast is open to all in
Chief Executive Jonathan Gear to Step Down as CEO and Member of the Board LONDON, Aug. 6, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced that the Board has appointed Matti Shem Tov, former CEO of ProQuest, as the Company's next CEO, effective August 9, 2024. Mr. Shem Tov will also join the Company's Board of Directors. Jonathan Gear, Chief Executive Officer, will step down as CEO and as a member of the Board at that time, and will transition into a non-executive role until November 1, 2024. "The Board
— Reaffirms 2024 Outlook — LONDON, Aug. 6, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenues of $650.3 million decreased 2.8%Organic revenues decreased 0.6%, as an increase in subscription revenues of 0.7% was offset by a decrease in re-occurring revenues of 0.7% and transactional and other revenues of 4.1%Net loss of $304.3 million; Net loss per diluted share of $0.46Adjuste
Delivering integrated, AI-enabled solutions specifically designed for patent preparation and prosecution LONDON, July 22, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced it has acquired Rowan TELS Corp. through a subsidiary. Rowan TELS Corp. is the provider of Rowan Patents – an integrated patent drafting and prosecution solution specially designed for patent practitioners to establish and protect patents more effectively. Clarivate enables organizations worldwide to confidently create, manage and protec
LONDON, July 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the second quarter 2024 before the market opens on Tuesday, August 6, 2024. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com. The Company will host a conference call and webcast at 9:00 AM Eastern Time on Tuesday, August 6, 2024 to review the results. The webcast is open to all intereste
LONDON, May 30, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT, CLVT PR A))) ("Clarivate"), a leading global provider of transformative intelligence, announced today that its 5.25% Series A Mandatory Convertible Preferred Shares (the "Preferred Shares"), will automatically and mandatorily convert into ordinary shares of Clarivate on June 3, 2024 (the "Conversion Date"). The mandatory conversion rate for each Preferred Share will be 3.8462 ordinary shares of Clarivate. Cash will be paid in lieu of fractional ordinary shares. As previously announced on May 1, 2024, holders of rec
— Reaffirms 2024 Outlook — LONDON, May 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Revenues of $621.2 million decreased 1.3%Organic revenues decreased 1.7%, as an increase in subscription revenues of 2.4% was more than offset by a decrease in transactional and other revenues of 11.4% and re-occurring revenues of 5.1%Net loss attributable to ordinary shares of $93.8 million; Net
LONDON, May 1, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT, CLVT PR A))) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the "Preferred Shares"), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024. On the mandatory conversion date, which is scheduled to occur on June 3, 2024, each Preferred Share will automatically and mandatorily convert into a num
Acquisition supports critical client workflow and reporting needs with proprietary SaaS platform, automating regulatory report authoring and compliance across manufacturing operations, supply chain and quality management LONDON, April 23, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced that it has acquired Global QMS, Inc., known as Global Q, a provider of cloud-based solutions that enable life sciences clients to automate regulatory reporting and compliance management. Financial terms of the transaction were not disclosed.